News

16 July 2018

Immunocore Announces Management Change

4 June 2018

Immunocore Presents New IMCgp100-102 Data that Show Durable Response and Robust Overall Survival Rate in Patients with Metastatic Uveal Melanoma

22 May 2018

Immunocore to Present New Data from IMCgp100-102 Trial in Metastatic Uveal Melanoma at 2018 ASCO Annual Meeting

21 May 2018

Immunocore wins Large Business of the Year at the 2018 Vale4Business Awards

8 February 2018

Immunocore Announces Leadership Change

4 January 2018

Immunocore Strengthens its Board with Appointments of Laura Wade-Gery and Kristine Peterson as Non-Executive Directors

11 December 2017

Immunocore’s IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma

13 November 2017

Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate

31 October 2017

Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

4 October 2017

Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer

News archive